Complete Genomics Announces Pricing of Initial Public Offering

/ Source: GlobeNewswire

MOUNTAIN VIEW, Calif., Nov. 11, 2010 (GLOBE NEWSWIRE) -- Complete Genomics, Inc. (Nasdaq:GNOM) announced the pricing of its initial public offering of 6,000,000 shares of its common stock at $9.00 per share. Complete Genomics has granted the underwriters a 30-day option to purchase up to 900,000 additional shares at the initial public offering price, less the underwriting discounts and commissions, to cover overallotments, if any. Complete Genomics' common stock will be listed on the NASDAQ Global Market under the symbol "GNOM" and will begin trading today, Thursday, November 11, 2010. All of the shares in the offering are being offered by Complete Genomics.

UBS Investment Bank and Jefferies & Company are acting as joint book-running managers for the offering, with Baird and Cowen and Company acting as co-managers.

A registration statement relating to these securities has been filed with, and declared effective by, the Securities and Exchange Commission. This press release shall neither constitute an offer to sell nor a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

This offering will be made only by means of a prospectus. Copies of the preliminary prospectus or, when available, the final prospectus, for this offering may be obtained from the prospectus department of UBS Investment Bank at 299 Park Avenue, New York, NY 10171, Attention: Prospectus Department or from Equity Syndicate Prospectus Department, Jefferies & Company, 520 Madison Avenue, 12th Floor, New York, NY 10022, at 877-547-6340, and at

About Complete Genomics

Complete Genomics is a life sciences company that has developed and commercialized an innovative DNA sequencing platform. The Complete Genomics Analysis Platform (CGA™ Platform) combines Complete Genomics' proprietary human genome sequencing technology with its advanced informatics and data management software and its innovative, end-to-end, outsourced service model to provide customers with data that is immediately ready to be used for genome-based research.

The Complete Genomics logo is available at

CONTACT: Complete Genomics, Inc. Investor Relations Scott Sandler (650) 943-2788 Jennifer Turcotte, Vice President of Marketing (650) 943-2846